News Releases

March 2020

March 2, 2020 3/2/2020 TAKEDA COMPLETES SALE OF SELECT OTC AND NON-CORE ASSETS TO ACINO

March 2, 2020 3/2/2020 TAKEDA AGREES TO DIVEST SELECT OTC AND NON-CORE ASSETS IN LATIN AMERICA TO HYPERA PHARMA FOR $825 MILLION USD

February 2020

February 28, 2020 2/28/2020 Takeda Receives Positive CHMP Opinion for Subcutaneous Vedolizumab as Maintenance Therapy in UC or CD

February 26, 2020 2/26/2020 Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

February 24, 2020 2/24/2020 Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer

February 14, 2020 2/14/2020 Investigational Subcutaneous Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active CD

February 5, 2020 2/5/2020 Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

February 4, 2020 2/4/2020 Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)

February 4, 2020 2/4/2020 Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive Reported Operating Profit

・For Shire news releases, click here